Clinical trials: Diabetic Macular Edema, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Diabetic Macular Edema
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Diabetic Macular Edema (DME)
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema
A multicenter, randomized, double-blind, parallel-group, active-controlled non-inferiority trial. A total of 406 subjects with diabetic macular edema (DME) were planned for enrollment.
- Trial name
- NCT07515079
- Testing
- BAT5906 injection, Lucentis
- Where
- 50 sites in China
- Volunteers
- 406 people
- Sponsor
- Bio-Thera Solutions
Center Involved Diabetic Macular Edema, Diabetic Macular Edema
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema
- Trial name
- DME (NCT05802329)
- Testing
- OCU200
- Where
- 5 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ocugen
Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration
Changes in Intraocular Pressure After Intravitreal Injection
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections introduce additional fluid volume into the eye, which can cause an acute, transient elevation in intraocular pressure (IOP).
- Conditions
- Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration, Retinal Vein Occlusion, Ocular Hypertension
- Trial name
- NCT07826286
- Volunteers
- 50 people
- Sponsor
- Assiut University
Diabetic Macular Edema (DME)
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with diabetic macular edema (DME).
- Trial name
- ATACAMA (NCT07841899)
- Testing
- OLN324, Aflibercept
- Volunteers
- 450 people
- Sponsor
- Ollin Biosciences, Inc.
Diabetic Macular Edema, Diabetic Retinopathy
A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.
THN391-OPT-101 is a study assessing safety and preliminary efficacy of THN391 in patients with diabetic macular edema (DME) given as monotherapy.
- Trial name
- NCT06701721
- Testing
- THN391
- Where
- 10 sites in Australia, Georgia
- Volunteers
- 21 people
- Sponsor
- Therini Bio Pty Ltd
Renal Function Disorder, Diabetic Macular Edema (DME)
Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients.
- Conditions
- Renal Function Disorder, Diabetic Macular Edema (DME), Neovascular Age Related Macular Degeneration
- Trial name
- NCT06929507
- Testing
- Intravitreal injection of Faricimab or Aflibercept 2 mg
- Where
- 2 sites in Greece
- Volunteers
- 60 people
- Sponsor
- University Hospital, Alexandroupolis
Diabetic Macular Edema (DME)
Suprachoroidal Bevacizumab Versus Intravitreal Bevacizumab in Diabetic Macular Edema
Diabetic macular edema is an eye condition caused by diabetes in which fluid accumulates in the central part of the retina, leading to blurred vision and potentially permanent vision loss.
- Trial name
- Macular Edema (NCT07897630)
- Testing
- Bevacizumab
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Khyber Teaching Hospital
Diabetic Macular Edema (DME)
A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME).
- Trial name
- QUELL-DME (NCT07812090)
- Testing
- Oral BGE-102, Anti-VEGF
- Where
- 16 sites in United States
- Volunteers
- 180 people
- Sponsor
- BioAge Labs, Inc.
Macular Edema, Macular Degeneration
Implementation of the Intravitreal Injection Administered by Nurses
Introduction: Intravitreal injections involve medication administration into the eye to treat ocular diseases and protect vision.
- Conditions
- Macular Edema, Macular Degeneration, Diabetic Macular Edema
- Trial name
- NCT06511700
- Testing
- It is a implementation a program incorporating nurses trained in administering intravitreal injections within the functional unit of Ophthalmology following the usual technique
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Corporacion Parc Tauli
Diabetic Macular Edema
Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT
Diabetic macular edema (DME) is a common cause of central visual loss in diabetic patients and a global public health burden around the world.
- Trial name
- DME HOME (NCT06610747)
- Testing
- Home-based Care Monitoring, Aflibercept 2Mg/0.05Ml Inj,Oph, Laser Treatment
- Where
- 4 sites in China
- Volunteers
- 308 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Macular Diseases
Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL
In just a few years, intravitreal injections have become a standard method of administration for certain retinal deseases (age-related macular degeneration [AMD], diabetic edematous maculopathy or retinal vein occlusion [RVO]).
- Trial name
- AFLIPIO (NCT06893965)
- Testing
- Intra ocular pressure Measure
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Non-Proliferative Diabetic Retinopathy
Intravitreal and Intracameral DEX in NPDR
To investigate the effects of intravitreal and intracameral injection of dexamethasone during cataract phacoemulsification in patients with mild to moderate non-proliferative diabetic retinopathy
- Trial name
- NCT06951087
- Testing
- Dexamethasone sodium phosphate
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Affiliated Hospital of Nantong University
Diabetic Macular Edema
Gene Therapy for Diabetic Macular Edema
FT-003 is a gene therapy product developed for the treatment of central involvement diabetic macular edema (CI-DME). Diabetic retinopathy is one of the most common microvascular complications of diabetes mellitus, and diabetic…
- Trial name
- NCT05916391
- Testing
- FT-003
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Frontera Therapeutics
Immunogenicity, Anti-drug Antibodies (ADAs)
Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema
Phase I, prospective, interventional, open-label, multicenter clinical trial to evaluate the safety of intravitreal PRO-169 through the presence of serum anti-drug antibodies (ADAs) to bevacizumab.
- Trial name
- NCT07429474
- Testing
- PRO-169
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Diabetic Macular Edema
South Asian Patients With Diabetic Macular Oedema Treated With Faricimab Assessing the Efficacy, Durability, and Safety (SEAFAR Study)
The YOSEMITE and RHINE trials, which studied DMO treated with faricimab, had a majority Caucasian cohort, and the small Asian cohort was East Asian, with no South Asian representation.
- Trial name
- SEAFAR (NCT07753616)
- Testing
- Intravitreal anti-VEGF injection, Faricimab
- Volunteers
- 120 people
- Sponsor
- Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust
Diabetic Retinopathy, Macular Edema
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME.
- Trial name
- NCT07705607
- Testing
- MK-8748, Aflibercept
- Where
- 20 sites in United States
- Volunteers
- 1,104 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Macular Edema
Gene Therapy for DME
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with Diabetic Macular Edema (DME).
- Trial name
- NCT06492876
- Testing
- FT-003
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Frontera Therapeutics
Diabetic Macular Edema (DME)
Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema
Diabetic macular edema is a frequent complication of long-standing diabetes mellitus in which fluid leaks into the central part of the retina (macula), leading to reduced vision.
- Trial name
- NCT07338097
- Testing
- Aflibercept (2.0 mg), Bevacizumab
- Where
- Pakistan
- Volunteers
- 116 people
- Sponsor
- CMH Multan Institute of Medical Sciences
Diabetic Macular Edema (DME)
Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients
This is a 12-month, prospective, randomized controlled, multi-center, open-label, superiority designed study. Treatment-Naïve DME patient with inflammatory biomarkers, who meet the inclusion and exclusion criteria, will be…
- Trial name
- DECADE (NCT07438119)
- Testing
- Combination Therapy with Aflibercept Intravitreous Injection (2mg) and Dexamethasone Intravitreal Implant, Aflibercept Intravitreous Injection (2mg) Monotherapy
- Volunteers
- 114 people
- Sponsor
- Kun Liu
Diabetic Macular Edema (DME)
Zhuochuming®-3T&E-DME Study (Treatment-naïve Patients)
The goal of this clinical trial is to understand whether Zhuochuming® (Aflibercept Intravitreal Injection) using a 3 loading doses followed by a treat-and-extend regimen (3+T\&E) can treat patients with diabetic macular edema…
- Trial name
- NCT07612904
- Testing
- Aflibercept Intravitreous Injection
- Where
- China
- Volunteers
- 186 people
- Sponsor
- The Third Peoples Hospital of Dalian